FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies

https://www.fda.gov/vaccines-blood-biologics/news-events-biologics/whats-new-biologics?utm_medium=email&utm_source=govdelivery